Analysts See $3.79 EPS for Regeneron Pharmaceuticals (REGN); Boston Scientific (BSX) Had 22 Bulls

November 2, 2017 - By Maria Brooks

Among 28 analysts covering Boston Scientific Corporation (NYSE:BSX), 22 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. Boston Scientific Corporation has $36 highest and $19 lowest target. $28.85’s average target is 3.59% above currents $27.85 stock price. Boston Scientific Corporation had 68 analyst reports since July 27, 2015 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Thursday, April 28. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Buy” rating by Nomura on Thursday, March 17. Jefferies maintained the shares of BSX in report on Friday, July 29 with “Hold” rating. The stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given on Thursday, July 23 by Benchmark. The rating was maintained by Needham with “Buy” on Friday, February 3. The firm has “Buy” rating given on Monday, July 10 by RBC Capital Markets. Wedbush maintained Boston Scientific Corporation (NYSE:BSX) rating on Friday, July 29. Wedbush has “Neutral” rating and $25 target. Needham maintained Boston Scientific Corporation (NYSE:BSX) on Thursday, October 26 with “Buy” rating. Suntrust Robinson initiated the stock with “Buy” rating in Thursday, February 25 report. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Buy” rating by BTIG Research on Sunday, September 6. See Boston Scientific Corporation (NYSE:BSX) latest ratings:

31/10/2017 Broker: SunTrust Rating: Buy New Target: $34.0 Maintain
27/10/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $30 New Target: $32 Maintain
26/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $32.0 Maintain
26/10/2017 Broker: Needham Rating: Buy New Target: $32.0 Maintain
24/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $36 Initiates Coverage On
11/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $30.0 Maintain
06/10/2017 Broker: Jefferies Rating: Hold New Target: $28.0 Maintain
02/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $31.0 Maintain
25/09/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $32.0 Maintain
05/09/2017 Broker: Jefferies Rating: Hold New Target: $28.0 Maintain

Analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report $3.79 EPS on November, 3.They anticipate $1.38 EPS change or 57.26% from last quarter’s $2.41 EPS. REGN’s profit would be $406.11M giving it 26.19 P/E if the $3.79 EPS is correct. After having $3.88 EPS previously, Regeneron Pharmaceuticals Inc’s analysts see -2.32% EPS growth. The stock decreased 1.40% or $5.62 during the last trading session, reaching $397. About shares traded. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since November 2, 2016 and is uptrending. It has outperformed by 0.70% the S&P500.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The company has market cap of $42.54 billion. The Firm commercializes medicines for eye diseases, high low-density lipoprotein cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. It has a 39.85 P/E ratio. The Company’s marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Since May 12, 2017, it had 1 insider purchase, and 7 insider sales for $42.75 million activity. 9,295 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares with value of $4.26M were sold by VAGELOS P ROY. 2,812 shares valued at $1.35M were sold by STAHL NEIL on Thursday, June 1. 21,147 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares with value of $9.90 million were sold by Terifay Robert J. Sanofi bought $65.06M worth of stock or 136,050 shares. $948,890 worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was sold by BROWN MICHAEL S. GOLDSTEIN JOSEPH L had sold 1,000 shares worth $482,550.

Among 29 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 14 have Buy rating, 2 Sell and 13 Hold. Therefore 48% are positive. Regeneron Pharmaceuticals Inc. has $700 highest and $300 lowest target. $522.64’s average target is 31.65% above currents $397 stock price. Regeneron Pharmaceuticals Inc. had 92 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was downgraded by Chardan Capital Markets to “Sell” on Wednesday, March 16. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Hold” rating by Jefferies on Thursday, October 5. The rating was initiated by Bernstein with “Outperform” on Wednesday, June 29. The rating was maintained by Jefferies with “Hold” on Monday, June 5. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Buy” rating given on Tuesday, August 4 by Chardan Capital Markets. The rating was maintained by BMO Capital Markets on Monday, September 11 with “Hold”. The firm earned “Hold” rating on Wednesday, September 27 by Oppenheimer. Goldman Sachs downgraded the shares of REGN in report on Thursday, February 16 to “Neutral” rating. The rating was maintained by Leerink Swann on Monday, April 4 with “Outperform”. The firm earned “Outperform” rating on Thursday, November 5 by RBC Capital Markets.

Investors sentiment increased to 1.38 in 2017 Q2. Its up 0.12, from 1.26 in 2017Q1. It is positive, as 42 investors sold Regeneron Pharmaceuticals Inc shares while 157 reduced holdings. 84 funds opened positions while 190 raised stakes. 71.53 million shares or 1.38% more from 70.55 million shares in 2017Q1 were reported. Natl Pension Serv holds 0.2% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) or 66,518 shares. 1,673 are held by Advisor Ptnrs Lc. Stratos Wealth Prtnrs reported 0.03% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Oakworth Capital, a Alabama-based fund reported 2 shares. Sumitomo Mitsui Trust Hldg Incorporated invested 0.16% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Lombard Odier Asset Mgmt (Europe) reported 955 shares. Bluemountain Cap Management Ltd Co invested in 2,322 shares or 0.02% of the stock. Asset Inc has invested 0.06% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Meiji Yasuda Asset Management holds 1,677 shares or 0.08% of its portfolio. Boston Common Asset Limited Liability reported 11,670 shares stake. Aviance Capital Prns Lc has invested 0.47% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). The Louisiana-based Iberiabank has invested 0.65% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Gulf Financial Bank (Uk) Ltd holds 24,485 shares or 0.17% of its portfolio. Tocqueville Asset Mgmt L P has 0.06% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Gideon Cap Advsr owns 566 shares for 0.31% of their portfolio.

Investors sentiment increased to 1.03 in Q2 2017. Its up 0.14, from 0.89 in 2017Q1. It is positive, as 41 investors sold Boston Scientific Corporation shares while 173 reduced holdings. 56 funds opened positions while 165 raised stakes. 1.22 billion shares or 0.64% less from 1.23 billion shares in 2017Q1 were reported. Ameriprise Fincl Inc invested in 1.91M shares or 0.03% of the stock. Greenwood Cap Associate Ltd Co owns 53,330 shares. Tributary Mgmt Ltd Liability owns 23,100 shares. State Bank Of America De has 0.04% invested in Boston Scientific Corporation (NYSE:BSX) for 7.50M shares. Sterling Cap has invested 0.08% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Cubist Systematic Strategies Ltd Liability invested 0.09% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Columbia L L C Inv Management accumulated 156,164 shares or 0.55% of the stock. Millennium Management Limited Liability Company holds 0.06% or 1.11 million shares. Oppenheimer reported 14,124 shares. Carlson Ltd Partnership invested 0.31% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Aqr Limited Liability Company has 1.79 million shares. Reynders Mcveigh Mngmt Limited Liability Com reported 15,892 shares. Clough Capital Prtn Lp stated it has 257,400 shares or 0.5% of all its holdings. Amica Pension Fund Board Of Trustees has 69,007 shares. Pggm Invs holds 0.03% or 232,120 shares.

The stock decreased 1.03% or $0.29 during the last trading session, reaching $27.85. About shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since November 2, 2016 and is uptrending. It has outperformed by 2.42% the S&P500.

Since May 17, 2017, it had 0 insider buys, and 5 selling transactions for $1.91 million activity. Shares for $82,313 were sold by Pierce David A. Phalen Michael P. also sold $422,369 worth of Boston Scientific Corporation (NYSE:BSX) shares. The insider Ballinger Kevin J. sold $754,454. Pratt Timothy A. also sold $271,261 worth of Boston Scientific Corporation (NYSE:BSX) shares.